What Happened
At EASD 2026, Eli Lilly highlighted data positioning its oral orforglipron, marketed as Foundayo, as delivering superior weight loss and blood-glucose reduction versus Novo Nordisk's oral semaglutide, the Wegovy pill, in type 2 diabetes. The comparison stands out as one of the first head-to-head evaluations of two oral GLP-1s against each other, a matchup the field had not seen much of before.
Two Oral GLP-1s, Two Designs
Both compounds are oral GLP-1s, but they are built differently, and that difference is central to understanding the comparison. Orforglipron is a small molecule. Oral semaglutide is a peptide. That structural distinction drives their practical profiles and much of what separates them in daily use.
Orforglipron, as a small molecule, can be taken at any time of day with no food or water restrictions. Oral semaglutide, as a peptide, requires a strict fasting-and-water protocol for absorption: it must be taken fasting with a small sip of water and separated from food and other medications, because its uptake is easily disrupted. So even before comparing efficacy, the two differ sharply in how they must be used, and that handling gap is one of the clearest contrasts within the oral GLP-1 category.
The Comparative Claim
At EASD, Eli Lilly presented data positioning Foundayo as delivering superior weight loss and blood-glucose reduction relative to the Wegovy pill in type 2 diabetes. As a manufacturer-highlighted comparison, the framing naturally favors the presenting company's product, and the appropriate reading is that the data were put forward in support of that position. The scientific community's scrutiny of such head-to-head claims is part of what venues like EASD provide, and independent evaluation is the right lens for interpreting any comparison a sponsor promotes.
Why an Oral-vs-Oral Comparison Is Notable
Much of the GLP-1 comparison landscape has pitted injectables against each other or injectables against pills. A direct oral-versus-oral comparison is comparatively new. It sharpens the question of how a small-molecule oral GLP-1 stacks up against a peptide-based one, both on efficacy and on the convenience dimensions that flow from their different chemistries. As the oral category grows, comparisons like this one help clarify that "oral GLP-1" is not a single thing but a set of meaningfully different products.
Beyond the efficacy claim, the dosing-flexibility gap is a substantive point of differentiation. A pill that can be taken any time without food or water restrictions poses a different daily routine than one requiring a strict fasting protocol. For a population managing type 2 diabetes, where multiple medications and routines are common, that difference is not trivial, and it may influence how consistently either compound is absorbed and used over time. Convenience and efficacy are distinct axes, and a full comparison has to weigh both.
What It Means
The Foundayo-versus-Wegovy-pill comparison marks an early entry in what is likely to be a growing set of oral GLP-1 head-to-heads. It underscores that the oral category is not monolithic: small-molecule and peptide oral GLP-1s differ meaningfully in both handling and, per the presented data, efficacy. As with any manufacturer-highlighted comparison, independent evaluation is the appropriate way to interpret the claims, and the field will look for corroborating analysis over time.
Important Note
This article is for educational and research reference purposes only. It does not provide dosing advice for human use. Peptide compounds discussed here are sold for research purposes, and nothing here constitutes medical advice. Approved medications should only be used under physician supervision.